The long-term goal of the Prostate Cancer Program is to address major clinical challenges associated with prostate cancer by applying knowledge of the basic biology of the disease. The goals of the Prostate Cancer Program, reflect the major investigational challenges with this disease: (i) to elucidate mechanisms underlying prostate cancer initiation;(ii) to understand whether and if so how cell types in the prostate contribute to the heterogeneity of the disease;(iii) to discriminate between men who should be treated for cure from those who do not require treatment;(iv) to improve and augment patient care and minimize racial disparities in care;and (v) to understand the relationship between bone biology and bone metastases. The hallmarks of the Prostate Cancer Program are its emphasis on these major clinical challenges and its exceptional integration of outstanding basic research and clinical studies to address these challenges. Thus, the major themes of the Prostate Program are: 1) Mechanisms and treatment of early stage prostate cancer;2) Mechanisms and treatment of advanced prostate cancer;and 3) Biology of bone and metastasis. The number of new prostate cancer patients seen has averaged 409/year. Of these many are low-risk patients that are followed without intervention. Of patients with advanced disease, 24/year (peak 30) have been enrolled on therapeutic clinical trials. 30% of patients accrued were minorities. Currently, the Prostate Cancer (PC) program consists of 21 members (12 full) from six departments within the College of Physicians and Surgeons, Mailman School of Public Health, and Columbia College. The program is enhanced by several multi-investigator grants including a NCI-funded program project grant and an NCI-funded UOl in the mouse models of human cancer consortium. For the last funding period of the grant (July 1, 2012 to June 30, 2013), the program received a total of $6.9M (direct costs) in cancer-relevant grant supporting including $2.2M (direct costs) in NCI funding, $3.4M (direct costs) in other cancer-related peer-reviewed funding, and $1.3M (direct costs) in other cancer-related non peer-reviewed funding. The total number of publications since the previous submission {i.e., 2008 to present) was 339, of which 14% were inter-programmatic, 19% intra-programmatic and 19% were in high impact journals (Impact Factor>10).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-40
Application #
8753112
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2019-06-30
Budget Start
2014-07-17
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
$33,319
Indirect Cost
$12,495
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sones, Jennifer L; Merriam, Audrey A; Seffens, Angelina et al. (2018) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J 32:2574-2586
Park, Karen Sophia; Xu, Christine L; Cui, Xuan et al. (2018) Reprogramming the metabolome rescues retinal degeneration. Cell Mol Life Sci 75:1559-1566
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793

Showing the most recent 10 out of 331 publications